Posts by cstephenson@legacymedsearch.com
Angel Medical Systems, Creator of the Guardian™, First Implantable Cardiac Alert System, Changes Name to Avertix Medical Inc. and Welcomes New CEO and CFO to Drive Continued Growth and Success
Angel Medical Systems Inc. (dba AngelMed), a company focused on improving long-term management of high-risk coronary disease in patients who have survived one or more heart attacks, today announced it has changed its corporate name to Avertix Medical Inc. (Avertix), and appointed Tim Moran as President and Chief Executive Officer and Philip Tom as Executive Vice…
Read MoreFive Years of Forbes | Legacy MEDSearch Ranks on the Forbes Best Executive Recruitment Firms for a Fifth Consecutive Year
ORLANDO, Fla., May 3, 2023 – Legacy MEDSearch has been named to the Forbes Best Executive Recruitment Firms and Forbes Best Professional Recruiting Firms out of over 25,000 recruitment and staffing firms in the United States, its fifth consecutive mention since 2019. Forbes Best Recruiting Firms lists are based on votes by industry professionals, who…
Read MoreClinical Study Results of the BlueWind System for Patients with Overactive Bladder Featured at the 2023 AUA Annual Meeting
BlueWind Medical, Ltd., the developer of a transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced results from the OASIS pivotal trial evaluating the safety and efficacy of the BlueWind System in the treatment of OAB. The results were featured in the late-breaking session (LBA01-05) at the American Urological Association (AUA) 2023 Annual Meeting…
Read MoreKerecis Combines Fish-Skin Graft and Silicone Cover for Wound Treatment
Kerecis® today announced MariGen® Shield, which integrates the company’s proven fish-skin graft with a silicone contact layer for treating chronic and complex wounds. The medical-fish-skin company also announced the results of a clinical study comparing the effectiveness of the Kerecis fish-skin grafts to a standard of care for diabetic foot ulcers. Both announcements were made at the Symposium…
Read MoreInnoblative Receives U.S. FDA Breakthrough Device Designation for its SIRA RFA Electrosurgical Device
Innoblative Designs, Inc. (Innoblative), a private medical device company addressing clinical unmet needs for patients with breast cancer, announced that it received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company’s SIRA™ RFA Electrosurgical Device (SIRA). The SIRA device is intended for use in breast cancer patients undergoing BCS, commonly…
Read MoreCardieX Receives FDA 510(K) Clearance for a World-First Vascular Biometric Monitor – the CONNEQT Pulse
CardieX Limited (ASX: CDX) (CardieX, the Company), today announced its new arterial health monitor, the CONNEQT Pulse (Pulse), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Pulse is the only vital signs monitor targeted at home, clinician, and clinical trial use that provides measurements of both brachial blood pressure (the pressure at…
Read MoreFirst Light Field-Enabled Spine Surgery Navigation Platform, Proprio Paradigm™, Receives FDA Clearance
Proprio, a Seattle-based medical technology company, today announced its surgical navigation platform, Paradigm, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Paradigm utilizes an advanced approach to replace traditional surgical navigation technologies that pull attention away from the patient and disrupt workflows in the process. Proprio’s Paradigm platform is the first to…
Read MoreBlackSwan Vascular Wins FDA Premarket Approval of Innovative New Treatment for Peripheral Arterial Hemorrhages
Bay Area-based BlackSwan Vascular, Inc., a privately held company that is developing innovative therapies in endovascular embolization, is pleased to announce it has received FDA Premarket Approval (PMA) of its Lava® Liquid Embolic System (Lava® LES) for treatment of peripheral arterial hemorrhage. Lava LES, a nonadhesive injectable, is the first liquid embolic product approved by…
Read MoreRapidAI Receives First and Only FDA 510(k) Clearance of Non-Contrast CT Imaging Product to Accelerate Acute Stroke Triage
RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for Rapid NCCT Stroke – a major addition to the RapidAI suite of non-contrast based solutions for stroke and trauma care, and the first and only FDA cleared medical device to detect suspected intracranial…
Read MoreCaristo Diagnostics Completes Series A Financing and Welcomes New CEO to Advance Ground-Breaking AI Technology for Cardiac Disease Detection
Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, today announced it has secured a further £13 million (US$16.3 million) to conclude its Series A financing round. Caristo will use the capital to advance its CaRi-Heart® technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in…
Read More